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  We developed novel gene vectors composed of dendrigraft poly-L-lysine (DGL).  
The transgene expression efficiency of the pDNA/DGL complexes (DGL complexes) 
was markedly higher than that of the control pDNA/poly-L-lysine complex.  However, 
the DGL complexes caused cytotoxicity and erythrocyte agglutination at high doses.  
Therefore, γ-polyglutamic acid (γ-PGA), which is a biodegradable anionic polymer, was 
added to the DGL complexes to decrease their toxicity. The resultant ternary complexes 
(DGL/γ-PGA complexes) were shown to be stable nanoparticles, and those with γ-PGA 
to pDNA charge ratios of >8 had anionic surface charges.  The transgene expression 
efficiency of the DGL/γ-PGA complexes was similar to that of the DGL complexes; 
however, they exhibited lower cytotoxicity and did not induce erythrocyte agglutination 
at high doses.  After being intravenously administered to mice, the DGL6 complex 
demonstrated high transfection efficiency in the liver, lungs, and spleen, whereas the 
DGL6/γ-PGA8 complex only displayed high transfection efficiency in the spleen. 
Future studies should examine the utility of DGL and DGL/γ-PGA complexes for 
clinical gene therapy. 
 
Abbreviations: DGL, dendrigraft poly-L-lysine; γ-PGA, γ-polyglutamic acid; PAMAM, 
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polyamidoamine; PLL, poly-L-lysine; WST-1, 
2-(4-iodophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium, monosodium 
salt; 1-methoxy PMS, 1-methoxy-5-methylphenazinium methyl sulfate; DMSO, 
dimethyl sulfoxide; Rh, rhodamine B isothiocyanate; EDTA, ethylenediaminetetraacetic 
acid; RLU, relative light units; CPZ, chlorpromazine 
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  In gene delivery, non-viral vectors, including cationic polymers, have several 
advantages, e.g., they are non-immunogenic; cause few acute toxicities; and their 
structural and chemical properties can be tightly controlled, which allows vehicles that 
are suitable for mass production to be designed [1,2].  Among non-viral vectors, 
cationic dendrimers are a new class of polymeric vectors in which hyperbranched 
macromolecules composed of layers of monomer units radiate from a central core. 
Dendrimers are monodispersed, stable, and of a defined size and are characterized by 
the presence of numerous ionizable terminal groups, which means that they can 
efficiently bind to a large amount of genetic material.  In addition, the electrostatic 
compaction of DNA by dendrimers was found to protect it from degradation by 
nucleases and to enhance the cellular uptake of dendrimer-based DNA-containing 
particles via adsorptive endocytosis or phagocytosis.  Polyamidoamine (PAMAM) 
dendrimers are commercially available macromolecules that can be used as carriers for 
plasmid DNA, antisense oligonucleotides, and siRNA [5-8].  However, PAMAM 
dendrimers are not biodegradable and exhibit strong cytotoxicity [9,10]. 
Therefore, we examined the utility of dendrigraft poly-L-lysine (DGL) polymers, a 
recently discovered subset of biodegradable dendritic polymers, which are usually 
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synthesized by protect/deprotect or activation schemes, as DNA vectors [11].  
Although the conventional dendritic poly-L-lysine compounds used for gene delivery 
are usually prepared from a non-biodegradable core, e.g., hexamethylenediamine or 
silsesquioxane cores [12-16], DGL, including its central core, consists entirely of lysine, 
and hence, is completely biodegradable.  In addition, DGL is water-soluble, thermally 
stable, and non-immunogenic.  In the present study, we developed a novel gene vector 
composed of DGL and investigated its efficacy and safety in vitro and in vivo. During 
the production of cationic dendrimer molecules, each complete grafting cycle; i.e., the 
formation of each layer, is referred to as a generation [3,4]. In a previous study 
examining 1st to 7th generation lysine dendrimers, the 5th and 6th generation lysine 
dendrimers were found to form stable complexes with pDNA and to have markedly 
higher gene transfection abilities than the other dendrimers [16].  We used 5th 
generation DGL polymers in this study. 
Unfortunately, it has been found that DGL vectors can induce toxicities due to their 
cationic properties.  However, the cytotoxic and blood component 
agglutination-inducing effects of cationic vectors such as DGL vectors can be countered 
by incorporating them in ternary complexes, which neutralizes their cationic charges. In 
fact, in a previous study we found that coating cationic complexes with a biodegradable 
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anionic polymer, γ-polyglutamic acid (γ-PGA), decreased their toxicity, without 
reducing their transgene expression efficiency [17]. Furthermore, the latter ternary 
complexes were constructed using a pharmaceutical, rather than a chemical, approach, 
which has several benefits, e.g., it makes manufacturing and sterilization easier.  In this 
study, we also developed γ-PGA-coated DGL vectors in an attempt to decrease the 
toxicity of DGL vectors. 
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2. Materials and methods 
2.1. Chemicals 
Poly-L-lysine compounds (PLL) (mean molecular weight: 22,500) were obtained 
from Sigma Chemical Co. (St. Louis, MO, USA), and 5th generation DGL compounds 
(MW: 172,300 Da, 963 lysine groups) were purchased from COLCOM S.A.S. 
(Montpellier, France).  γ-PGA was provided by Yakult Pharmaceutical Industry Co., 
Ltd. (Tokyo, Japan).  Bovine serum albumin (BSA) was purchased from Sigma 
Aldrich (St. Louis, MO, U.S.A.), and fetal bovine serum (FBS) was purchased from 
Biological Industries Ltd. (Kibbutz Beit Haemek, Israel).  RPMI 1640, Opti-MEM I, 
antibiotics (100 U/mL penicillin and 100 µg/mL streptomycin), and the other culture 
reagents were obtained from GIBCO BRL (Grand Island, NY, USA).  
2-(4-iodophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium, monosodium 
salt (WST-1), and 1-methoxy-5-methylphenazinium methyl sulfate (1-methoxy PMS) 
were purchased from Dojindo Laboratories (Kumamoto, Japan).  Rhodamine-PLL 
(Rh-PLL) and rhodamine-DGL (Rh-DGL) were prepared in our laboratory.  Briefly, 
PLL or DGL and rhodamine B isothiocyanate were dissolved in dimethyl sulfoxide 
(DMSO) and stirred overnight at room temperature in the dark.  The resultant Rh–PLL 
and Rh-DGL were purified by gel filtration.  Almost 1.5% of the PLL and DGL 
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molecules were labeled with rhodamine B.  All other chemicals were of reagent grade. 
 
2.2 Preparation of pDNA, binary complexes, and ternary complexes 
pCMV-Luc was constructed by subcloning the Hind III/Xba I firefly luciferase cDNA 
fragment from the pGL3-control vector (Promega, Madison, WI, USA) into the 
polylinker of the pcDNA3 vector (Invitrogen, Carlsbad, CA, USA).  The resultant 
pDNA was amplified using an EndoFree Plasmid Giga Kit (QIAGEN GmbH, Hilden, 
Germany), before being dissolved in 5% dextrose solution and stored at -80 °C until the 
analysis.  The pDNA concentration of the solution was assessed by measuring the 
absorbance of the solution at 260 nm and adjusted to 1 mg/mL. 
To prepare the binary complexes, pDNA solution and PLL solution or DGL solution 
(pH 7.4) were mixed by thorough pipetting, before being left for 20 min at room 
temperature. PLL, which like DGL is entirely composed of lysine, was used as a control 
vector.  The charge ratio of the pDNA/PLL complex (PLL complex) was 1:8, whereas 
pDNA/DGL complexes with charge ratios of 1:2, 4, 6, 8, or 10 (the DGL2, 4, 6, 8, or 10 
complexes) were produced.  To construct the ternary complexes, γ-PGA was mixed 
with the DGL6 complex by pipetting to produce complexes with charge ratios of 1:6:2, 
1:6:4, 1:6:6, 1:6:8, 1:6:10, and 1:6:12 (the DGL6/PGA2, 4, 6, 8, 10, and 12 complexes), 
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which were then left for another 20 min at room temperature. 
 
2.3. Physicochemical properties of the complexes 
The particle sizes and ζ-potentials of each complex were measured using a Zetasizer 
Nano ZS (Malvern Instruments, Ltd., Malvern, United Kingdom).  Particle size is 
shown as the number-weighted mean diameter. 
To assess complex formation, 20-µL aliquots of each complex solution containing 1 
µg pDNA were mixed with 4 µL loading buffer (30% glycerol and 0.2% bromophenol 
blue) and loaded onto 0.8% agarose gel. Electrophoresis (i-Mupid J; Cosmo Bio, Tokyo, 
Japan) was carried out at 50 V in running buffer solution (40 mM Tris/HCl, 40 mM 
acetic acid, and 1 mM ethylenediaminetetraacetic acid (EDTA)) for 60 min, and pDNA 
retardation was visualized with ethidium bromide staining. 
 
2.4. In vitro gene expression and cellular uptake experiments 
B16-F10 cells, a mouse melanoma cell line, were obtained from the Cell Resource 
Center for Biomedical Research (Tohoku University, Japan).  The cells were 
maintained in RPMI 1640 supplemented with 10% FBS and antibiotics (culture 
medium) in a humidified atmosphere of 5% CO2 in air at 37 °C, before being plated on 
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24-well plates (Becton-Dickinson, Franklin Lakes, NJ, USA) at a density of 1.0 × 104 
cells/well and cultivated in 500 µL culture medium.  In the transfection experiment, 
the medium was replaced with 500 µL Opti-MEM I medium after 24 h pre-incubation, 
and then the cells were treated with each complex (containing 1 µg pCMV-Luc) and 
incubated for 2 h.  After the cells had been transfected, the Opti-MEM I medium was 
replaced with culture medium, and the cells were cultured for a further 22 h in a 
humidified atmosphere of 5% CO2 in air at 37 °C.  After 22 h incubation, the cells 
were washed with phosphate-buffered saline (PBS) and then lysed in 100 µL lysis 
buffer (pH 7.8; 0.1 M Tris/HCl buffer containing 0.05% Triton X-100 and 2 mM EDTA).  
Ten-microliter lysate samples were mixed with 50 µL of the luciferase assay buffer 
(PicaGene; Toyo Ink, Tokyo, Japan), and the amount of fluorescence produced was 
immediately measured using a luminometer (Lumat LB 9507; EG & G Berthold, Bad 
Wildbad, Germany).  The protein content of the lysate was determined in a Bradford 
assay (Bio-Rad Laboratories, Inc., Hercules, CA, USA) in which BSA was used as a 
standard and absorbance was measured using a microplate reader (Sunrise RC-R; Tecan 
Japan Co., Ltd., Kanagawa, Japan) at 595 nm.  Luciferase activity is shown as relative 
light units (RLU) per mg protein. 
To visualize the uptake of the complexes, B16-F10 cells were transfected with 
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complexes composed of pCMV-Luc and Rh-PLL or Rh-DGL, as described above.  
After 22 h incubation, the relative levels of Rh-PLL and Rh-DGL in the cells were 
characterized using fluorescence microscopy (200 × magnification). 
 
2.5. pH titration of PLL complex, DGL complex, and DGL/PGA complex 
  The PLL, DGL, or DGL/PGA complex was titrated using 2N sodium hydroxide 
(NaOH).  Each solution had its pH adjusted to 3.0, and then the solutions were titrated 
with 2N NaOH.  The resultant pH changes were recorded using a pH meter (LAQUA; 
HORIBA Ltd., Kyoto, Japan) and plotted to allow the buffering capacities of each 
complex to be compared. 
 
2.6. WST-1 assay 
  Tests examining the cytotoxic effects of the various complexes on B16-F10 cells 
were carried out using a WST-1-based commercially available cell proliferation reagent.  
The reagent was prepared (5 mM WST-1 and 0.2 mM 1-methoxy PMS in PBS) and 
filtered through a 0.22 µm filter (Millex-GP; Millipore Co, Bedford, MA, USA) just 
before the experiments.  B16-F10 cells were plated on 96-well plates 
(Becton-Dickinson) at a density of 3.0 × 103 cells/well in culture medium.  Complexes 
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containing 1 µg pDNA in 100 µL Opti-MEM I medium were added to each well and 
incubated for 2 h.  Then, the medium was replaced with 100 µL culture medium and 
incubated for another 22 h at 37 °C.  The medium was then substituted for 100 µL 
culture medium, and 10 µL of the WST-1 reagent were added to each well.  The cells 
were incubated for an additional 2 h at 37 °C, and the absorbance of each well was 
measured at a wavelength of 450 nm (reference wavelength: 630 nm) using a microplate 
reader.  The results are shown as percentages of the value for the untreated cells. 
 
2.7. Inhibition study 
  To determine the endocytotic pathway used to transport the complexes into the cells, 
the cells were subjected to 23 h pre-incubation, before being treated with 0.014 mM 
chlorpromazine (CPZ), as an inhibitor of clathrin-mediated endocytosis; 0.2 mM 
genistein, as an inhibitor of caveolae-mediated endocytosis; or 1 mM amiloride, as an 
inhibitor of macropinocytosis, for 1 h.  After the cells had been treated in the 
abovementioned manner, the DGL6 or DGL6/γ-PGA8 complex was added to the media 
containing each inhibitor, and then the cells were incubated for 2 h at 37 °C.  After 2 h 
transfection, the medium was replaced with culture medium, the cells were cultured for 
a further 22 h at 37 °C, and then their luciferase activity was determined.  The results 
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are shown as percentages of the values for the untreated cells. 
 
2.8. Animals 
  All animal care and experimental procedures were performed in accordance with the 
Guidelines for Animal Experimentation of Nagasaki University after receiving approval 
from the institutional animal care and use committee.  Male ddY mice (5-weeks-old) 
were purchased from Japan SLC (Shizuoka, Japan).  After being delivered, the mice 
were allowed to acclimatize to their new environment for at least one day before the 
experiments. 
 
2.9. In vivo study 
  Two hundred and fifty µL of the DGL6 or DGL6/γ-PGA8 complex (containing 40 µg 
pCMV-Luc) were intravenously injected into each mouse to examine the transgene 
expression efficiency of these complexes.  Six hours after being injected with the 
complexes, the mice were sacrificed, and the liver, kidneys, spleen, heart, and lungs 
were dissected.  The tissues were washed twice with cold saline and homogenized with 
lysis buffer.  The resultant homogenates were centrifuged at 15,000 rpm (Kubota 3500) 
for 5 min, and the associated supernatants were subjected to luciferase assays.  
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Luciferase activity is indicated as RLU per gram of tissue. 
 
2.10. Agglutination study 
Mouse erythrocytes were subjected to three rounds of centrifugation at 5000 rpm at 
4 °C (Kubota 3500; Kubota, Tokyo, Japan) for 5 min and then resuspended in PBS (a 
2% (v/v) stock suspension was prepared). DGL6 or DGL6/γ-PGA8 complexes were 
added to samples of the erythrocyte suspension (complex: stock suspension = 1:1), 
which were then incubated for 15 min at room temperature.  Next, 10 µL of each 
sample were placed on a glass plate, and the extent of agglutination within the samples 
was assessed by microscopy (200 × magnification). 
 
2.11. Statistical analysis 
The statistical significance of differences between two groups was assessed using the 
Student’s t test. Multiple comparisons among the groups were performed using 





3.1. Physicochemical properties and electrophoretic assay of PLL and DGL 
complexes 
   A PLL complex with a PLL to pDNA charge ratio of 8 was used as a control for the 
comparisons with the DGL complexes.  The particle sizes and ζ-potentials of the PLL 
and DGL complexes are summarized in Table 1.  The PLL complex had a particle size 
of 76.4 ± 12.8 nm and a ζ-potential of 48.4 ± 0.3 mV.  The DGL complexes had 
particle sizes of approximately 30–158 nm and ζ-potentials of 34–46 mV. 
   During a gel retardation assay, naked pDNA was detected as bands on agarose gel. 
On the other hand, no such bands were detected in the lanes for the PLL and DGL 
complexes (Fig. 1). These findings confirmed that both PLL and DGL were able to form 
stable pDNA-containing complexes. 
 
3.2. In vitro transfection efficiency and buffering capacity of the PLL and DGL 
complexes 
  B16-F10 cells were transfected with the PLL complex or one of the DGL complexes, 
incubated for 22 h, and then had their luciferase activity evaluated.  The in vitro 
transgene expression efficiencies of the PLL and DGL complexes are shown in Fig. 2.  
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The PLL complexes displayed low transgene expression levels.  Conversely, the 
transgene expression levels of the cells that were transfected with the DGL complexes 
were over 100-fold higher than those seen in the cells transfected with PLL complexes.  
Among the cells that were transfected with the DGL complexes, luciferase activity 
increased with the amount of DGL contained within the complex, up to a charge ratio of 
6, and then gradually decreased.   
  Other B16-F10 cells were transfected with PLL or DGL complexes containing 
Rh-PLL or Rh-DGL to allow the uptake of the complexes to be visualized (Fig. 3).  As 
a result, many red dots representing Rh-PLL or Rh-DGL were observed in most of the 
transfected cells. 
  The results of the experiment assessing the buffering capacity of the DGL and PLL 
complexes are shown in Fig. 4.  The DGL complexes exhibited higher buffering 
capacity than the PLL complex between pH 5 and 7. 
 
3.3. Physicochemical properties and electrophoretic assay of the DGL/γ-PGA 
complexes 
  On the basis of our findings regarding the physicochemical properties of the 
complexes and the results of the in vitro transfection experiments, we prepared a 
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number of ternary complexes containing the DGL6 complex and varying amounts of 
γ-PGA. The particle sizes and ζ-potentials of these DGL6/γ-PGA complexes are shown 
in Table 2.  DGL6/γ-PGA complexes with γ-PGA to pDNA charge ratios of >8 
exhibited particle sizes of ~100 nm, while the DGL6/γ-PGA4 complex tended to 
aggregate.  The addition of γ-PGA decreased the ζ-potential of the DL6 complex in a 
concentration-dependent manner.  The DGL6/γ-PGA complexes with charge ratios >8 
had anionic surface charges. 
  As was done for the PLL and DGL complexes, gel retardation assays were performed 
to examine whether that the DGL6/γ-PGA complexes were stable DNA vectors (Fig. 5).  
Once again, no bands representing naked pDNA were detected in the lanes for the 
DGL6/γ-PGA complexes, indicating that they were stable DNA vectors. 
 
3.4. In vitro transfection efficiency of the DGL/γ-PGA complexes 
  Next, the DGL/γ-PGA complexes were incubated with B16-F10 cells, incubated for 
22 h, and then had their luciferase activity determined.  The in vitro transgene 
expression efficiencies of DGL/γ-PGA complexes with various charge ratios are shown 
in Fig. 6.  The transgene expression efficiency of the DGL6 complex exceeded 109 
RLU/mg protein, whereas that of the DGL6/γ-PGA2 complex was ~1010 RLU/mg 
17 
 
protein, and the luciferase activity induced by the complexes decreased as the amount of 
γ-PGA contained within them increased.  The luciferase activity of each DGL6/γ-PGA 
complex was higher than that of the DGL6 complex.   Also, the DGL6/γ-PGA8 




  To evaluate the cytotoxicity of the complexes, each complex was added to B16-F10 
cells, and then the viability of the cells was evaluated using the WST-1 assay (Fig. 7).  
The DGL6 complex displayed significantly greater cytotoxicity than the control (P 
<0.01).  However, the addition of γ-PGA decreased the cytotoxicity of the DGL6 
complex, and the DGL6/γ-PGA complexes with charge ratios of 6-10 did not markedly 
affect the viability of the B16-F10 cells.   
 
3.6. Inhibition study 
  On the basis of our findings regarding the physicochemical properties of the 
complexes and the results of the in vitro transfection experiments and the WST-1 assay, 
the DGL6 and DGL6/γ-PGA8 complexes were subjected to an inhibition study in order 
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to examine the mechanisms responsible for their uptake.  As a result, it was found that 
endocytotic inhibitors decreased the transgene expression efficiencies of the DGL6 and 
DGL6/γ-PGA8 complexes (Fig. 8).  Namely, CPZ, an inhibitor of clathrin-mediated 
endocytosis, and genistein, an inhibitor of caveolae-mediated endocytosis, decreased the 
transgene expression efficiencies of the DGL6 complex to about 25% and 7%, 
respectively.  In addition, the inhibition of macropinocytosis with amiloride decreased 
the transgene expression efficiency of the DGL6 complex to ~50%.  On the other hand, 
the transgene expression efficiency of the DGL6/γ-PGA8 complex was only 
significantly suppressed by genistein. 
 
3.7. In vivo study 
  Next, the in vivo transgene expression efficiency of the DGL6 and DGL6/γ-PGA8 
complexes was examined in ddY male mice (Fig. 9).  The luciferase activity levels of 
several tissues were determined at 6 h after the intravenous administration of the 
complexes.  The DGL6 complex induced gene expression in the liver, spleen, and 
lungs.  On the other hand, the DGL6/γ-PGA8 complex only induced markedly high 




3.8. Agglutination study 
   As previous studies have found that DGL vectors induced agglutination, the extent 
of the erythrocyte agglutination induced by the DGL6/γ-PGA8 complex was compared 
with that induced by the DGL6 complex (Fig. 10).  Microscopic examinations 
demonstrated that the DGL6 complex caused severe agglutination while the 




  DGL is a type of a dendrigraft polymer composed of naturally occurring amino acid 
(lysine) monomers, making it favorable for biomedical applications.  In this study, we 
attempted to develop new biodegradable gene vectors composed of DGL. First, it was 
important to confirm that DGL is able to form stable complexes with pDNA. 
Electrophoresis demonstrated that DGL formed stable self-assembling 
pDNA-containing nanoparticles; i.e., no bands for naked pDNA were detected in the 
lanes for the DGL complexes. In addition, the physicochemical properties of 
biodegradable gene vectors, such as their particle size and ζ-potential, have important 
effects on their transfection efficiency.  For example, a previous study reported that 
cells commonly take up complexes measuring fifty to several hundred nanometers in 
diameter [18]. Thus, the particle sizes of the DGL DNA vectors produced in the present 
study were measured, and it was found that they varied from 30-158 nm (Table 1), 
which would put them roughly within the range described above. However, they also 
exhibited positive surface charges, which might be disadvantageous as cationic particles 
have been shown to have cytotoxic effects.   
  Next, we compared the transfection efficiency and cellular uptake of each complex in 
B16-F10 cells.  The gene expression levels induced by the DGL complexes were 
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100-fold higher than those induced by the control PLL complex (Fig. 2), although 
strong cellular uptake of both the PLL and DGL complexes was observed during 
experiments involving complexes containing Rh-PLL or Rh-DGL (Fig. 3). Yamagata et 
al. also reported that another type of poly-L-lysine induced markedly higher dendrimer 
gene expression than PLL [12].  Generally, non-viral gene carriers with strong pH 
buffering abilities are able to promote endosomal escape, resulting in an increase in 
gene transfection efficiency.  In this study, pH titration demonstrated that the DGL 
complexes had higher buffering capacity than the PLL complex (Fig. 4).  Thus, the 
marked difference between the gene expression levels induced by the DGL and PLL 
complexes might have mainly been caused by variations in the frequency of endosome 
escape. However, a previous study also showed that lysine dendrimers facilitate DNA 
transcription; i.e., a lysine dendrimer was found to cause less pDNA compaction than 
PLL [12]. 
  Many cationic non-viral gene vectors have been reported to cause cytotoxicity due 
the strong affinity of positively charged particles for the cellular membrane [19].  In 
this study, the DGL complexes also exhibited cytotoxicity at high doses.  One 
promising approach to overcoming such cytotoxicity is the addition of anionic polymers 
to cationic complexes.  For example, we previously found that γ-PGA decreased the 
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toxicity of cationic compounds [17].  Therefore, in the present study various amounts 
of γ-PGA were added to the DGL6 complex to produce ternary complexes (DGL/γ-PGA 
complexes). 
γ-PGA is known to be biocompatible and is produced by microbial species typified 
by Bacillus subtilis [28].  Moreover, a previous study found that synthesized γ-PGA 
had negligible toxic effects on the human B-cell line EHRB, even at a concentration of 
100 mg/L, whilst another study found that when 1 mg γ-PGA was injected into mice it 
had no toxic effects and did not cause any immunological or inflammatory reactions [29, 
30]. 
The addition of γ-PGA to the DGL6 complex decreased its ζ-potential in a 
concentration-dependent manner, and the DGL/γ-PGA complexes with γ-PGA to pDNA 
charge ratios of >8 exhibited anionic surface charges (Table 2).  Interestingly, the 
particle sizes of the DGL/γ-PGA complexes were not larger than those of the DGL 
complexes; therefore, γ-PGA might have increased the compaction of the DGL 
complexes via electrostatic interactions.  The negative surface charges possessed by 
the DGL/γ-PGA complexes with γ-PGA to pDNA charge ratios of >8 indicate that these 
particles contained γ-PGA on their outer surfaces. Worryingly, some anionic polymers, 
such as heparin sulfate and heparan sulfate, have been shown to cause pDNA to be 
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released from pDNA/cationic polymer complexes [20, 21].  However, the addition of 
γ-PGA to the DGL6 complex did not result in pDNA release (Fig. 5).  In addition, the 
anionically charged DGL/γ-PGA complexes exhibited markedly decreased cytotoxicity 
compared with the DGL complexes (Fig. 7). 
Anionic complexes are generally not taken up by cells because they electrostatically 
repulse the cellular membrane.  However, we previously found that a γ-PGA-coated 
complex with an anionic charge was taken up via a γ-PGA-specific receptor-mediated 
energy-dependent process [17].  In agreement with this, the DGL/γ-PGA complexes 
with anionic surface charges were found to be stronger inducers of transgene expression 
than the DGL complexes (Fig. 6).  In particular, the markedly high transgene 
expression induced by the DGL6/γ-PGA 2 complex might be worth investigating in a 
future study.  Also, the DGL/γ-PGA complexes continued to display sufficient 
buffering capacity (Fig. 4). 
To clarify the mechanisms responsible for the uptake of the complexes, we compared 
the uptake pathway of the anionic DGL6/γ-PGA8 complex with that of the cationic 
DGL6 complex.  CPZ, genistein, and amiloride all suppressed the transgene 
expression efficiency of the DGL6 complex, suggesting that it was taken up by the cells 
via several mechanisms, including caveolae-mediated endocytosis and 
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clathrin-mediated endocytosis (Fig. 8A).  On the other hand, the transgene expression 
efficiency of the DGL6/γ-PGA8 complex was only suppressed by the addition of 
genistein (Fig. 8B).  These results suggested that the DGL/γ-PGA complexes were 
taken up by caveolae-mediated endocytosis, which could be advantageous as it has been 
reported that caveolae-mediated uptake does not lead to lysosomal degradation [22,23].  
Based on these findings, we consider that the charge ratio of DGL to γ-PGA might 
affect the cellular uptake pathways of DGL/γ-PGA complexes. 
    A previous study showed that cationic non-viral gene vectors caused the 
agglutination of blood components such as erythrocytes and albumin because of their 
strong electrostatic interactions [24].  Such agglutination often leads to adverse effects, 
including embolisms and inflammatory reactions.  In the current study, the DGL6 
complex induced transient erythrocyte agglutination at high doses, as shown in Fig. 10.  
In contrast, the DGL6/γ-PGA8 complex did not cause any agglutination.  Thus, 
changing the polarity of the surface charge of the DL6 complex from positive to 
negative appeared to have reduced its interactions with blood components. 
  DGL complexes are biodegradable nanoparticles that exhibit high transfection 
efficiency.  Furthermore, in the present study DGL/γ-PGA complexes exhibited similar 
transfection efficiency to DGL complexes whilst displaying decreased toxicity.  In 
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addition, after being injected into mice the DGL6 complex induced marked gene 
expression in the liver, spleen, and lung (Fig. 9A), which makes sense as nanoparticles 
are taken up by the reticuloendothelial system.  On the other hand, the DGL6/γ-PGA8 
complex only induced strong gene expression in the spleen (Fig. 9B). Sutherland et al. 
reported that poly-γ-D-glutamic acid (γDPGA), which is a capsular component of 
Bacillus anthracis, mainly accumulated in the spleen and liver after its intravenous 
injection into mice [26, 27].  Therefore, the DGL/γ-PGA complexes examined in the 
present study might have accumulated in the spleen via the same mechanism.  We 
previously reported that a pDNA/polyethylenimine/γ-PGA complex, which also induced 
strong gene expression in the spleen, was an effective DNA vaccine against malaria [25].  





  We developed novel gene vectors composed of DGL.  Whilst the transfection 
efficiency of the developed DGL complexes was sufficiently high, the addition of 
γ-PGA to the complexes decreased their cytotoxicity and their tendency to induce 
erythrocyte agglutination.  However, whilst the DGL6 complex induced marked gene 
expression in the liver, spleen, and lungs of mice, the DGL6/γ-PGA8 complex only 
induced strong gene expression in the spleen. Future studies should examine whether 
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Figure 1. Electrophoretic analysis of the PLL and DGL complexes 
  The complexes were loaded onto agarose gel, and electrophoresis was carried out. 
pDNA retardation was visualized using ethidium bromide. 
 
Figure 2. In vitro transfection efficiencies of the PLL and DGL complexes   
B16-F10 cells were transfected with various PLL- or DGL-containing complexes.  
Twenty-two hours after being transfected, the cells were lysed, and their luciferase 
activity was determined.  Each bar represents the mean ± S.E. (n = 3).  **P <0.01 vs. 
PLL complex. 
 
Figure 3. Fluorescence microscopy images of transfected B16-F10 cells  
B16-F10 cells were transfected with Rh-PLL- or Rh-DGL-containing complexes.  
Twenty-four hours after the cells had been transfected, the uptake of Rh-PLL (i) and 
Rh-DGL (ii) was assessed (200 × magnification). 
 
Figure 4. Buffering capacity of the PLL, DGL, and DGL/γ-PGA complexes 
  The pH of each complex solution was adjusted to 3.0, and then each solution was 
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titrated using 2N NaOH.  : PLL8 complex, : DGL6 complex, and : 
DGL6/γ-PGA8 complex. 
 
Figure 5. Electrophoretic analysis of the DGL and DGL/γ-PGA complexes 
The complexes were loaded onto agarose gel, and electrophoresis was carried out. 
pDNA retardation was visualized using ethidium bromide. 
 
Figure 6. In vitro transfection efficiencies of the DGL/γ-PGA complexes  
 B16-F10 cells were transfected with the DGL6 complex or one of the 
DGL6/γ-PGA-containing complexes.  Twenty-two hours after being transfected, the 
cells were lysed, and their luciferase activity was determined.  Each bar represents the 
mean ± S.E. (n = 3).  *P <0.05, **P <0.01 vs. DGL complex. 
 
Figure 7. Cytotoxicity of the DGL6 and DGL/γ-PGA complexes towards B16-F10 
cells   
The viability of B16-F10 cells treated with the DGL6 complex or one of the 
DGL6/γ-PGA-containing complexes was measured using the WST-1 assay.  The cells 
were incubated with the complexes for 2 h, and their viability was measured at 22 h 
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after treatment.  Data are shown as percentages of the value for the untreated cells.  
Each bar represents the mean ± S.E. (n = 8).  *P <0.05, **P <0.01 vs. control. 
 
Figure 8. Influence of endocytotic inhibitors on the transgene expression efficiency 
of the DGL6 (A) and DGL6/γ-PGA8 complexes (B) 
 B16-F10 cells were transfected with the DGL6 or DGL6/γ-PGA8 complex in medium 
containing various endocytotic inhibitors.  Twenty-two hours after being transfected, 
the cells had their luciferase activity evaluated.  Data are shown as percentages of the 
value for the untreated cells.  Each bar represents the mean ± S.E. (n = 4).  **P <0.01 
vs. control. 
 
Figure 9. In vivo transgene expression efficiency of the DGL6 (A) and 
DGL6/γ-PGA8 complexes (B) in mice 
  The complexes were intravenously injected into mice (40 µg DNA per mouse). Six 
hours after being injected, the mice were sacrificed, and each organ was dissected and 
had its luciferase activity quantified.  Each bar represents the mean ± S.E. (n = 4). 
 
Figure 10. Erythrocyte agglutination induced by the complexes  
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  Erythrocytes were treated with the DGL6 or DGL6/γ-PGA8 complex, and the 
resultant agglutination was observed by microscopy (200 × magnification). (A) PBS, 
(B) DGL6 complex, and (C) DGL6/γ-PGA8 complex. 
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